Abstract
Purpose
To identify the practice patterns related to use of surveillance mammography in male breast cancer (MaBC) survivors.
Methods
Using administrative claims data from OptumLabs Data Warehouse, we identified men who underwent surgery for breast cancer during 2007–2017. We calculated the proportion of men who had at least one mammogram (a) within 13 months for all patients and (b) within 24 months amongst those who maintained their insurance coverage for at least that length of time after surgery. Multivariate logistic regression modeling was used to identify factors associated with mammography within each timeframe.
Results
Out of 729 total MaBC survivors, 209 (29%) underwent mammography within 13 months after surgery. Among those who had lumpectomy, 41% underwent mammography, whereas among those who had mastectomy, 27% had mammography. Amongst 526 men who maintained consistent insurance coverage for 24 months after surgery, 215 (41%) underwent mammography at least once during that 24-month period. In this cohort, the proportion who had at least one mammogram during the 24-month period was 49% after lumpectomy and 40% after mastectomy. In a multivariate logistic regression model, more recent diagnosis (2015+) and older age at diagnosis were associated with lower odds of undergoing mammography, while receipt of radiation was associated with higher odds of undergoing mammography.
Conclusions
Although recent ASCO guidelines recommend surveillance mammography after lumpectomy, a minority of MaBC survivors undergo surveillance mammography, even after lumpectomy. This is likely due to the paucity of data regarding the true benefits and harms of surveillance/screening mammography for MaBC.
This is a preview of subscription content, log in via an institution to check access.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34
Leon-Ferre RA, Giridhar KV, Hieken TJ et al (2018) A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 37:599–614
National Comprehensive Cancer Network (2020) NCCN clinical practice guidelines in oncology. Breast Cancer Version 3.2019
Hassett MJ, Somerfield MR, Baker ER et al (2020) Management of male breast cancer: ASCO guideline. J Clin Oncol 38(16):1849–1863
Wallace PJ, Shah ND, Dennen T et al (2014) Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 33:1187–1194
Ruddy KJ, Sangaralingham L, Freedman RA et al (2018) Adherence to guidelines for breast surveillance in breast cancer survivors. J Natl Compr Canc Netw 16:526–534
Auvinen A, Curtis RE, Ron E (2002) Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 94:1330–1332
Satram-Hoang S, Ziogas A, Anton-Culver H (2007) Risk of second primary cancer in men with breast cancer. Breast Cancer Res 9:R10
Ferzoco RM, Ruddy KJ (2015) Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer (Dove Med Press) 7:371–379
Pritzlaff M, Summerour P, McFarland R et al (2017) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161:575–586
Wang YA, Jian J-W, Hung C-F et al (2018) Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer 18:315
Dong C, Hemminki K (2001) Second primary breast cancer in men. Breast Cancer Res Treat 66:171–172
Funding
This study was supported in part by the Tracy Starr Breast Cancer Research Fund Award (KJR).
Author information
Authors and Affiliations
Contributions
Study conception and design: SY and KJR; Data acquisition: LS and SRP; Writing—initial draft: SY, LS, SRP and KJR; Data analysis: LS and SRP; Data interpretation: All authors; Writing—final review and approval: All authors;
Corresponding author
Ethics declarations
Conflict of interest
Karthik V. Giridhar has received travel costs to his institution from Menarini Silicon Biosystems to attend an investigators’ meeting for work performed outside of the current study. Tina J. Hieken has received grants from Genentech for work performed outside of the current study. Judy C. Boughey has received grants from Eli Lilly & Co. for work performed outside of the current study. Roberto A. Leon‐Ferre has received travel support from Immunomedics for work performed outside of the current study. Rachel A Freedman has received institutional funding from Eisai, Puma, and Genentech. Sadia Khanani has a research grant from Siemens Healthineers and has a research and development agreement with Imago Systems. Rafael E. Jimenez is a consultant with Histowiz, Inc. The other authors made no disclosures.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Yadav, S., Sangaralingham, L., Payne, S.R. et al. Surveillance mammography after treatment for male breast cancer. Breast Cancer Res Treat 194, 693–698 (2022). https://doi.org/10.1007/s10549-022-06645-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-022-06645-w